country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-120764

Copy Link Print Information

PF-46396

PF-46396 is a potent HIV-1 inhibitor with an EC₅₀ value of 0.206 µM. PF-46396 shows antiviral activity. PF-46396 inhibits the processing of capsid (CA)/spacer peptide 1 (SP1) (p25) Gag precursor proteins and blocks maturation of the viral core particle.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 1207481-21-7
分子式: C₂₇H₂₉F₃N₂O
分子量:454.53

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (268 KB)

PF-46396 構造式

CAS 番号: 1207481-21-7

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
化学情報
プロトコル (1)
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

^[1]

HIV-1

0.206 μM (EC₅₀)

HIV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CEM-SS	CC₅₀	20 μM Compound: PF-46396	Cytotoxicity against human CEM-SS cells after 6 days by XTT assay Cytotoxicity against human CEM-SS cells after 6 days by XTT assay	[PMID: 19805571]
CEM-SS	EC₅₀	>20 μM Compound: PF-46396	Antiviral activity against HIV1 RF infected in human CEM-SS cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 RF infected in human CEM-SS cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]
HeLa	EC₅₀	>10 μM Compound: PF-46396	Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	>10 μM Compound: PF-46396	Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	>3.2 μM Compound: PF-46396	Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.206 μM Compound: PF-46396	Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
MT2	CC₅₀	15 μM Compound: PF-46396	Cytotoxicity against human MT2 cells after 6 days by XTT assay Cytotoxicity against human MT2 cells after 6 days by XTT assay	[PMID: 19805571]
MT2	EC₅₀	>16 μM Compound: PF-46396	Antiviral activity against HIV1 RF infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 RF infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]
MT2	EC₅₀	0.017 μM Compound: PF-46396	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]
MT2	EC₅₀	0.21 μM Compound: PF-46396	Antiviral activity against HIV1 92HT599 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days Antiviral activity against HIV1 92HT599 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days	[PMID: 19805571]
MT2	EC₅₀	0.24 μM Compound: PF-46396	Antiviral activity against HIV1 92HT594 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days Antiviral activity against HIV1 92HT594 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days	[PMID: 19805571]
MT2	EC₅₀	0.36 μM Compound: PF-46396	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]

化学情報

CAS 番号 1207481-21-7
分子量 454.53
分子式 C₂₇H₂₉F₃N₂O
SMILES

O=C1C(C(F)(F)F)=CC=CN1CC(NC2CC3=C(C=CC=C3)C2)C4=CC=C(C(C)(C)C)C=C4
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

プロトコル

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (268 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Blair WS, et al . New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother. 2009 Dec;53(12):5080-7. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ